Maura J. O’Neill

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.

The paper identifies a novel proteasome-binding site in E6AP mediated by hRpn10, showing E6AP's unique interaction with the proteasome for substrate ubiquitination.